4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Show more...
CEO
Dr. Jason Loveridge B.Sc., B.Sc, Ph.D., FRSM
Funcionários
33
País
DE
ISIN
DE000A3E5C40
WKN
000A3E5C4
Listagens
0 Comments
Compartilhe suas ideias
FAQ
Qual é o preço da ação da 4 SC hoje?▼
O preço atual de VSC.XETRA é €2.98 EUR — aumentou +0% nas últimas 24 horas. Acompanhe mais de perto o desempenho da ação 4 SC no gráfico.
Qual é o símbolo da ação da 4 SC?▼
Dependendo da bolsa, o símbolo da ação pode variar. Por exemplo, na bolsa , as ações da 4 SC são negociadas sob o símbolo VSC.XETRA.